Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 12773393 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Soloaga A, et al. (2003) MSK2 and MSK1 mediate the mitogen- and stress-induced phosphorylation of histone H3 and HMG-14. EMBO J 22, 2788-97 12773393
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S133-p - CREB (mouse)
Orthologous residues
CREB (human): S133‑p, CREB iso2 (human): S119‑p, CREB (mouse): S133‑p, CREB (rat): S133‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  Coffin-Lowry syndrome
 Relevant cell lines - cell types - tissues:  fibroblast
 Cellular systems studied:  primary cells
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
anisomycin increase
phorbol ester increase

K5-m2 - H3 (mouse)
Orthologous residues
H3 (human): K5‑m2, HIST2H3A/C/D (human): K5‑m2, H3 (mouse): K5‑m2, H3 iso2 (mouse): K5‑m2, H3 iso3 (mouse): K5‑m2, H3 (rat): K5‑m2, H3 iso3 (rat): K5‑m2, H3 (pig): K5‑m2, H3 (chicken): K5‑m2, H3 (cow): K5‑m2
Characterization
 Methods used to characterize site in vivo modification-specific antibody, western blotting
 Relevant cell lines - cell types - tissues:  fibroblast-embryo [MSK1 (mouse), homozygous knockout], fibroblast-embryo [MSK2 (mouse), homozygous knockout]
 Cellular systems studied:  primary cells
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
trichostatin A no change compared to control wild-type
trichostatin A no change compared to control MSK1/MSK2 KO
phorbol ester no change compared to control wild-type
phorbol ester no change compared to control MSK1/MSK2 KO
phorbol ester, trichostatin A no change compared to control wild-type
phorbol ester, trichostatin A no change compared to control MSK1/MSK2 KO
anisomycin no change compared to control wild-type
anisomycin no change compared to control MSK1/MSK2 KO
anisomycin, trichostatin A no change compared to control wild-type
anisomycin, trichostatin A no change compared to control MSK1/MSK2 KO

K10-a - H3 (mouse)
Orthologous residues
H3 (human): K10‑a, H3 (mouse): K10‑a, H3 iso2 (mouse): K10‑a, H3 iso3 (mouse): K10‑a, H3 (rat): K10‑a, H3 iso3 (rat): K10‑a, H3 (pig): K10‑a, H3 (chicken): K10‑a, H3 (cow): K10‑a
Characterization
 Methods used to characterize site in vivo modification-specific antibody, western blotting
 Relevant cell lines - cell types - tissues:  fibroblast-embryo [MSK1 (mouse), homozygous knockout], fibroblast-embryo [MSK2 (mouse), homozygous knockout]
 Cellular systems studied:  primary cells
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
trichostatin A increase wild-type
trichostatin A increase MSK1/MSK2 KO
phorbol ester no change compared to control wild-type
phorbol ester no change compared to control MSK1/MSK2 KO
phorbol ester, trichostatin A increase wid-type
phorbol ester, trichostatin A increase MSK1/MSK2 KO
anisomycin no change compared to control wild-type
anisomycin no change compared to control MSK1/MSK2 KO
anisomycin, trichostatin A increase wild-type
trichostatin A, anisomycin increase MSK1/MSK2 KO
trichostatin A no change compared to control wild-type
trichostatin A no change compared to control MSK1/MSK2 KO
phorbol ester no change compared to control wild-type
phorbol ester no change compared to control MSK1/MSK2 KO
phorbol ester, trichostatin A no change compared to control wild-type
phorbol ester, trichostatin A no change compared to control MSK1/MSK2 KO
anisomycin no change compared to control wild-type
anisomycin no change compared to control MSK1/MSK2 KO
anisomycin, trichostatin A no change compared to control wild-type
anisomycin, trichostatin A no change compared to control MSK1/MSK2 KO

K10-m2 - H3 (mouse)
Orthologous residues
H3 (human): K10‑m2, H3 (mouse): K10‑m2, H3 iso2 (mouse): K10‑m2, H3 iso3 (mouse): K10‑m2, H3 (rat): K10‑m2, H3 iso3 (rat): K10‑m2, H3 (pig): K10‑m2, H3 (chicken): K10‑m2, H3 (cow): K10‑m2
Characterization
 Methods used to characterize site in vivo modification-specific antibody, western blotting
 Relevant cell lines - cell types - tissues:  fibroblast-embryo [MSK1 (mouse), homozygous knockout], fibroblast-embryo [MSK2 (mouse), homozygous knockout]
 Cellular systems studied:  primary cells
 Species studied:  mouse

S11-p - H3 (mouse)
Orthologous residues
H3 (human): S11‑p, H3 (mouse): S11‑p, H3 iso2 (mouse): S11‑p, H3 iso3 (mouse): S11‑p, H3 (rat): S11‑p, H3 iso3 (rat): S11‑p, H3 (pig): S11‑p, H3 (chicken): S11‑p, H3 (cow): S11‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  Coffin-Lowry syndrome
 Relevant cell lines - cell types - tissues:  fibroblast, fibroblast-embryo [MSK1 (mouse), homozygous knockout], fibroblast-embryo [MSK2 (mouse), homozygous knockout]
 Cellular systems studied:  primary cells
 Species studied:  human, mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
trichostatin A decrease
SB203580, PD184352 trichostatin A no effect upon treatment-induced decrease
anisomycin increase
PD184352 anisomycin no effect upon treatment-induced increase
SB203580 anisomycin inhibit treatment-induced increase
SB203580, PD184352 anisomycin inhibit treatment-induced increase
trichostatin A, anisomycin increase
PD184352 anisomycin, trichostatin A no effect upon treatment-induced increase
SB203580 anisomycin, trichostatin A inhibit treatment-induced increase
SB203580, PD184352 anisomycin, trichostatin A inhibit treatment-induced increase
phorbol ester increase
PD184352 phorbol ester inhibit treatment-induced increase
SB203580 phorbol ester no effect upon treatment-induced increase
SB203580, PD184352 phorbol ester inhibit treatment-induced increase
phorbol ester, trichostatin A increase
PD184352 phorbol ester, trichostatin A inhibit treatment-induced increase
SB203580 phorbol ester, trichostatin A no effect upon treatment-induced decrease
SB203580, PD184352 phorbol ester, trichostatin A inhibit treatment-induced increase
anisomycin increase wild-type
anisomycin decrease MSK1 KO
anisomycin no change compared to control MSK2 KO
anisomycin no change compared to control MSK1/MSK2 knockout
anisomycin, trichostatin A increase wild-type
trichostatin A, anisomycin decrease MSK1 KO
trichostatin A, anisomycin no change compared to control MSK2 KO
trichostatin A, anisomycin no change compared to control MSK1 MSK2 KO
phorbol ester increase wild-type
phorbol ester decrease MSK1 KO
phorbol ester no change compared to control MSK2 KO
phorbol ester no change compared to control MSK1/MSK2 KO
phorbol ester, trichostatin A increase wild-type
phorbol ester, trichostatin A no change compared to control MSK1 KO
phorbol ester, trichostatin A no change compared to control MSK2 KO
phorbol ester, trichostatin A no change compared to control MSK1/ MSK2 KO
anisomycin increase
phorbol ester increase

K15-a - H3 (mouse)
Orthologous residues
H3 (human): K15‑a, H3 (mouse): K15‑a, H3 iso2 (mouse): K15‑a, H3 iso3 (mouse): K15‑a, H3 (rat): K15‑a, H3 iso3 (rat): K15‑a, H3 (pig): K15‑a, H3 (chicken): K15‑a, H3 (cow): K15‑a
Characterization
 Methods used to characterize site in vivo modification-specific antibody, western blotting
 Relevant cell lines - cell types - tissues:  fibroblast-embryo [MSK1 (mouse), homozygous knockout], fibroblast-embryo [MSK2 (mouse), homozygous knockout]
 Cellular systems studied:  primary cells
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
trichostatin A increase wild-type
trichostatin A increase MSK1/MSK2 KO
phorbol ester no change compared to control wild-type
phorbol ester no change compared to control MSK1/MSK2 KO
phorbol ester, trichostatin A increase wid-type
phorbol ester, trichostatin A increase MSK1/MSK2 KO
anisomycin no change compared to control wild-type
anisomycin no change compared to control MSK1/MSK2 KO
anisomycin, trichostatin A increase wild-type
anisomycin, trichostatin A increase MSK1/MSK2 KO

K19-a - H3 (mouse)
Orthologous residues
H3 (human): K19‑a, H3 (mouse): K19‑a, H3 iso2 (mouse): K19‑a, H3 iso3 (mouse): K19‑a, H3 (rat): K19‑a, H3 iso3 (rat): K19‑a, H3 (pig): K19‑a, H3 (chicken): K19‑a, H3 (cow): K19‑a
Characterization
 Methods used to characterize site in vivo modification-specific antibody, western blotting
 Relevant cell lines - cell types - tissues:  fibroblast-embryo [MSK1 (mouse), homozygous knockout], fibroblast-embryo [MSK2 (mouse), homozygous knockout]
 Cellular systems studied:  primary cells
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
trichostatin A increase wild-type
trichostatin A increase MSK1/MSK2 KO
phorbol ester no change compared to control wild-type
phorbol ester no change compared to control MSK1/MSK2 KO
phorbol ester, trichostatin A increase wid-type
phorbol ester, trichostatin A increase MSK1/MSK2 KO
anisomycin no change compared to control wild-type
anisomycin no change compared to control MSK1/MSK2 KO
anisomycin, trichostatin A increase wild-type
anisomycin, trichostatin A increase MSK1/MSK2 KO

K24-a - H3 (mouse)
Orthologous residues
H3 (human): K24‑a, H3 (mouse): K24‑a, H3 iso2 (mouse): K24‑a, H3 iso3 (mouse): K24‑a, H3 (rat): K24‑a, H3 iso3 (rat): K24‑a, H3 (pig): K24‑a, H3 (chicken): K24‑a, H3 (cow): K24‑a
Characterization
 Methods used to characterize site in vivo modification-specific antibody, western blotting
 Relevant cell lines - cell types - tissues:  fibroblast-embryo [MSK1 (mouse), homozygous knockout], fibroblast-embryo [MSK2 (mouse), homozygous knockout]
 Cellular systems studied:  primary cells
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
trichostatin A increase wild-type
trichostatin A increase MSK1/MSK2 KO
phorbol ester no change compared to control wild-type
phorbol ester no change compared to control MSK1/MSK2 KO
phorbol ester, trichostatin A increase wid-type
phorbol ester, trichostatin A increase MSK1/MSK2 KO
anisomycin no change compared to control wild-type
anisomycin no change compared to control MSK1/MSK2 KO
anisomycin, trichostatin A increase wild-type
anisomycin, trichostatin A increase MSK1/MSK2 KO

S29-p - H3 (mouse)
Orthologous residues
H3 (human): S29‑p, H3 (mouse): S29‑p, H3 iso2 (mouse): S29‑p, H3 iso3 (mouse): S29‑p, H3 (rat): S29‑p, H3 iso3 (rat): S29‑p, H3 (pig): S29‑p, H3 (chicken): S29‑p, H3 (cow): S29‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  fibroblast-embryo [MSK1 (mouse), homozygous knockout], fibroblast-embryo [MSK2 (mouse), homozygous knockout]
 Cellular systems studied:  primary cells
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
SB203580, PD184352 no change compared to control
trichostatin A no change compared to control
SB203580, PD184352 trichostatin A no change compared to control
anisomycin increase
PD184352 anisomycin no effect upon treatment-induced increase
SB203580 anisomycin inhibit treatment-induced increase
SB203580, PD184352 anisomycin inhibit treatment-induced increase
anisomycin, trichostatin A increase
PD184352 anisomycin, trichostatin A no effect upon treatment-induced increase
SB203580 anisomycin, trichostatin A inhibit treatment-induced increase
SB203580, PD184352 anisomycin, SB203580, trichostatin A inhibit treatment-induced increase
phorbol ester increase
PD184352 phorbol ester inhibit treatment-induced increase
SB203580 phorbol ester no effect upon treatment-induced increase
SB203580, PD184352 phorbol ester inhibit treatment-induced increase
phorbol ester, trichostatin A increase
PD184352 phorbol ester, trichostatin A inhibit treatment-induced increase
SB203580 phorbol ester, trichostatin A no effect upon treatment-induced decrease
SB203580, PD184352 phorbol ester, trichostatin A inhibit treatment-induced increase
anisomycin increase wild-type
anisomycin decrease MSK1 KO
anisomycin no change compared to control MSK2 KO
anisomycin no change compared to control MSK1/MSK2 KO
trichostatin A, anisomycin increase wild-type
trichostatin A, anisomycin anisomycin, trichostatin A no effect upon treatment-induced increase MSK1 KO
trichostatin A, anisomycin decrease MSK2 KO
trichostatin A, anisomycin no change compared to control MSK1/MSK2 KO
phorbol ester no change compared to control wild-type
phorbol ester no change compared to control MSK1 KO
phorbol ester no change compared to control MSK2 KO
phorbol ester no change compared to control MSK1/MSK2 KO
phorbol ester, trichostatin A increase wild-type
phorbol ester, trichostatin A decrease MSK1 KO
phorbol ester, trichostatin A no change compared to control MSK2 KO
phorbol ester, trichostatin A no change compared to control MSK1?MSK2 KO

S7-p - HMGN1 (mouse)
Orthologous residues
HMGN1 (human): S7‑p, HMGN1 (mouse): S7‑p, HMGN1 (rat): S7‑p, HMGN1 (cow): S7‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  fibroblast-embryo [MSK1 (mouse), homozygous knockout], fibroblast-embryo [MSK2 (mouse), homozygous knockout]
 Cellular systems studied:  primary cells
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PD184352, SB203580 no change compared to control
trichostatin A no change compared to control
PD184352, SB203580 trichostatin A no change compared to control
anisomycin increase
PD184352 anisomycin no effect upon treatment-induced increase
SB203580 anisomycin inhibit treatment-induced increase
SB203580, PD184352 anisomycin inhibit treatment-induced increase
anisomycin, trichostatin A increase
PD184352 anisomycin, trichostatin A no effect upon treatment-induced increase
SB203580 anisomycin, trichostatin A inhibit treatment-induced increase
SB203580, PD184352 anisomycin, SB203580, trichostatin A inhibit treatment-induced increase
phorbol ester increase
PD184352 phorbol ester inhibit treatment-induced increase
SB203580 phorbol ester no effect upon treatment-induced increase
PD184352, SB203580 phorbol ester inhibit treatment-induced increase
phorbol ester, trichostatin A increase
PD184352 phorbol ester, trichostatin A inhibit treatment-induced increase
SB203580 phorbol ester, trichostatin A no effect upon treatment-induced decrease
PD184352, SB203580 phorbol ester, trichostatin A inhibit treatment-induced increase
anisomycin increase wild-type
anisomycin decrease MSK1 KO
anisomycin no change compared to control MSK2 KO
anisomycin no change compared to control MSK1/MSK2 KO
anisomycin, trichostatin A increase wild-type
anisomycin, trichostatin A anisomycin, trichostatin A no effect upon treatment-induced increase MSK1 KO
anisomycin, trichostatin A decrease MSK2 KO
anisomycin, trichostatin A no change compared to control MSK1/MSK2 KO
phorbol ester increase wild-type
phorbol ester decrease MSK1 KO
phorbol ester decrease MSK2 KO
phorbol ester no change compared to control MSK1/MSK2 KO
phorbol ester, trichostatin A increase wild-type
phorbol ester, trichostatin A decrease MSK1 KO
phorbol ester, trichostatin A decrease MSK2 KO
phorbol ester, trichostatin A no change compared to control MSK1/MSK2 KO


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.